1. |
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin, 2018, 68(1): 7-30.
|
2. |
Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin, 2016, 66(2): 115-132.
|
3. |
Mirnezami R, Nicholson J, Darzi A. Preparing for precision medicine. N Engl J Med, 2012, 366(6): 489-491.
|
4. |
Bailey P, Chang DK, Nones K, et al. Genomic analyses identify molecular subtypes of pancreatic cancer. Nature, 2016, 531(7592): 47-52.
|
5. |
Tempero MA, Malafa MP, Al-Hawary M, et al. Pancreatic adenocarcinoma, version 2.2017, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw, 2017, 15(8): 1028-1061.
|
6. |
Zhang Y, Huang J, Chen M, et al. Preoperative vascular evaluation with computed tomography and magnetic resonance imaging for pancreatic cancer: a meta-analysis. Pancreatology, 2012, 12(3): 227-233.
|
7. |
Motosugi U, Ichikawa T, Morisaka H, et al. Detection of pancreatic carcinoma and liver metastases with gadoxetic acid-enhanced MR imaging: comparison with contrast-enhanced multi-detector row CT. Radiology, 2011, 260(2): 446-453.
|
8. |
Holzapfel K, Reiser-Erkan C, Fingerle AA, et al. Comparison of diffusion-weighted MR imaging and multidetector-row CT in the detection of liver metastases in patients operated for pancreatic cancer. Abdom Imaging, 2011, 36(2): 179-184.
|
9. |
Jha P, Bijan B, Melendres G, et al. Hybrid imaging for pancreatic malignancy: clinical applications, merits, limitations, and pitfalls. Clin Nucl Med, 2015, 40(3): 206-213.
|
10. |
Kysucan J, Lovecek M, Klos D, et al. Benefit of PET/CT in the preoperative staging in pancreatic carcinomas. Rozhl Chir, 2010, 89(7): 433-440.
|
11. |
Tatsumi M, Isohashi K, Onishi H, et al. 18F-FDG PET/MRI fusion in characterizing pancreatic tumors: comparison to PET/CT. Int J Clin Oncol, 2011, 16(4): 408-415.
|
12. |
Joo I, Lee JM, Lee DH, et al. Preoperative assessment of pancreatic cancer with FDG PET/MR imaging versus FDG PET/CT plus contrast-enhanced multidetector CT: a prospective preliminary study. Radiology, 2017, 282(1): 149-159.
|
13. |
Donati OF, Hany TF, Reiner CS, et al. Value of retrospective fusion of PET and MR images in detection of hepatic metastases: comparison with 18F-FDG PET/CT and Gd-EOB-DTPA-enhanced MRI. J Nucl Med, 2010, 51(5): 692-699.
|
14. |
中华医学会外科学分会胰腺外科学组. 胰腺癌诊治指南(2014). 中华外科杂志, 2014, 52(12): 831-837.
|
15. |
Richardson W, Stefanidis D, Mittal S, et al. SAGES guidelines for the use of laparoscopic ultrasound. Surg Endosc, 2010, 24(4): 745-756.
|
16. |
Habr F, Akerman P. Role of endoscopic ultrasound in the diagnosis and staging of pancreatic cancer. Front Biosci, 2000, 5: E30-E35.
|
17. |
Yang R, Lu M, Qian X, et al. Diagnostic accuracy of EUS and CT of vascular invasion in pancreatic cancer: a systematic review. J Cancer Res Clin Oncol, 2014, 140(12): 2077-2086.
|
18. |
Gaujoux S, Allen PJ. Role of staging laparoscopy in peri-pancreatic and hepatobiliary malignancy. World J Gastrointest Surg, 2010, 2(9): 283-290.
|
19. |
Tran Cao HS, Kaushal S, Metildi CA, et al. Tumor-specific fluorescence antibody imaging enables accurate staging laparoscopy in an orthotopic model of pancreatic cancer. Hepatogastroenterology, 2012, 59(118): 1994-1999.
|
20. |
王槐志. 可能切除胰腺癌的外科治疗. 中华消化外科杂志, 2016, 15(6): 543-546.
|
21. |
杨尹默. 可能切除的胰腺癌外科治疗争议与共识. 中国实用外科杂志, 2015, 35(1): 54-56.
|
22. |
Laurence JM, Tran PD, Morarji K, et al. A systematic review and meta-analysis of survival and surgical outcomes following neoadjuvant chemoradiotherapy for pancreatic cancer. J Gastrointest Surg, 2011, 15(11): 2059-2069.
|
23. |
White RR, Tyler DS. Neoadjuvant therapy for pancreatic cancer: the Duke experience. Surg Oncol Clin N Am, 2004, 13(4): 675-684.
|
24. |
Mokdad AA, Minter RM, Zhu H, et al. Neoadjuvant therapy followed by resection versus upfront resection for resectable pancreatic cancer: a propensity score matched analysis. J Clin Oncol, 2017, 35(5): 515-522.
|
25. |
Golcher H, Brunner TB, Witzigmann H, et al. Neoadjuvant chemoradiation therapy with gemcitabine/cisplatin and surgery versus immediate surgery in resectable pancreatic cancer: results of the first prospective randomized phaseⅡtrial. Strahlenther Onkol, 2015, 191(1): 7-16.
|
26. |
陈琦, 魏涛, 陈怡文, 等. 2017年美国临床肿瘤学会年会胰腺癌研究进展解析. 中华消化外科杂志, 2017, 16(7): 684-688.
|
27. |
Hartwig W, Strobel O, Hinz U, et al. CA19-9 in potentially resectable pancreatic cancer: perspective to adjust surgical and perioperative therapy. Ann Surg Oncol, 2013, 20(7): 2188-2196.
|
28. |
Katz MH, Pisters PW, Evans DB, et al. Borderline resectable pancreatic cancer: the importance of this emerging stage of disease. J Am Coll Surg, 2008, 206(5): 833-846.
|
29. |
Liu L, Xu H, Wang W, et al. A preoperative serum signature of CEA+/CA125+/CA19-9≥ 1000 U/mL indicates poor outcome to pancreatectomy for pancreatic cancer. Int J Cancer, 2015, 136(9): 2216-2227.
|
30. |
Khorana AA, Mangu PB, Berlin J, et al. Potentially curable pancreatic cancer: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol, 2016, 34(21): 2541-2556.
|